It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Background
The skin is both a target and a potential conduit for the delivery of drugs, but its cornified cell layer resists penetration by most molecules. This study investigated the potential of superparamagnetic iron oxide nanoparticles to facilitate the transdermal delivery of anticancer agents.
Results
Chemotherapeutic cancer drugs were applied with or without nanoparticles to the skin of hairless mice, and their ability to penetrate the skin was assessed using fluorescence microscopy and tumor growth. Nanoparticles enhanced the penetration of the skin by doxorubicin and 5-fluorouracil as determined by fluorescence microscopy and growth retardation of experimental melanoma in immunocompetent, syngeneic mice. This drug enhancement did not require conjugation or encapsulation of the drugs by the nanoparticles—simple co-administration sufficed. Nanoparticles applied topically to melanomas increased the cytotoxicity and immune cell infiltration induced by co-administered 5-fluorouracil, and also reduced vascularization of the tumors independently of 5-fluorouracil.
Conclusion
Correctly formulated superparamagnetic iron oxide nanoparticles can facilitate the chemotherapeutic effectiveness of cytotoxic drugs on skin tumors by both increasing their transdermal penetration and ameliorating host–tumor interactions. This enhancement of skin penetration occurs without the need for conjugation or encapsulation of the co-administered drugs, and so will likely be applicable to other drugs, also.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 The University of Sydney, Key Centre for Polymers and Colloids, School of Chemistry, Sydney, Australia (GRID:grid.1013.3) (ISNI:0000 0004 1936 834X); The University of Sydney, Dermatology, Sydney Medical School, and Centenary Institute, Sydney, Australia (GRID:grid.1013.3) (ISNI:0000 0004 1936 834X)
2 The University of Sydney, Key Centre for Polymers and Colloids, School of Chemistry, Sydney, Australia (GRID:grid.1013.3) (ISNI:0000 0004 1936 834X); The University of Sydney, Northern Clinical School and Kolling Institute, Sydney, Australia (GRID:grid.1013.3) (ISNI:0000 0004 1936 834X)
3 The University of Sydney, Key Centre for Polymers and Colloids, School of Chemistry, Sydney, Australia (GRID:grid.1013.3) (ISNI:0000 0004 1936 834X)
4 Conde S. Januário Hospital, Department of Anatomical Pathology, Macao, China (GRID:grid.460996.4) (ISNI:0000 0004 1798 3082)
5 The University of Sydney, Dermatology, Sydney Medical School, and Centenary Institute, Sydney, Australia (GRID:grid.1013.3) (ISNI:0000 0004 1936 834X)
6 Zeta Therapeutics Pty Ltd, and Sirtex Medical Ltd, Sydney, Australia (GRID:grid.481858.8) (ISNI:0000 0004 6007 6736)
7 The University of Sydney, Dermatology, Sydney Medical School, and Centenary Institute, Sydney, Australia (GRID:grid.1013.3) (ISNI:0000 0004 1936 834X); Royal Prince Alfred Hospital, Dermatology, Cancer Services, Sydney, Australia (GRID:grid.413249.9) (ISNI:0000 0004 0385 0051); The University of Sydney, Royal Prince Alfred Hospital, Immune Imaging, Centenary Institute, Camperdown, Australia (GRID:grid.413249.9)